Crossmark

Agile 3+ and 4 Scores Accurately Predict Major Adverse Liver Outcomes, Liver Transplant, Progression of MELD Score, the Development of Hepatocellular Carcinoma, and Death in NAFLD

Crossref DOI link: https://doi.org/10.1007/s10620-025-08850-1

Published Online: 2025-03-24

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Truong, Emily

Alnimer, Lynna

Gornbein, Jeffrey A.

Yang, Ju Dong

Alkhouri, Naim

Harrison, Stephen A.

Noureddin, Mazen
License Information

Text and Data Mining valid from 2025-03-24

Version of Record valid from 2025-03-24
More Information

Article History

Received: 18 May 2024

Accepted: 4 January 2025

First Online: 24 March 2025

Declarations

:

: M.N. has been on the advisory board/consultant for 89BIO, Altimmune, Gilead, cohBar, Cytodyn, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Madrgial, NorthSea, Prespecturm, Terns, Siemens and Roche diagnostic; MN has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking and Zydus; MN is a shareholder or has stocks in Anaetos, Chrownwell, Ciema, Rivus Pharma and Viking. All other authors declare no conflicts of interest.

: None.

: This study is a retrospective in nature with no therapeutic intervention. The study data are confidential. Drs. Mazen Noureddin have access to the data. De-identified data might be provided upon request in compliance with patient privacy rules.

Document is current

Any future updates will be listed below